These results suggested that recipient IL-15 rs10519613 polymorphism could discriminate the clinical outcome of HCC patients within or beyond the UCSF criteria and might affect follow-up and therapeutic strategies after LT. The gene discussed is IL15; the disease is hepatocellular carcinoma.